This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NOVA2 / RNA-binding protein Nova-2 · IHC design guide
Design Immunohistochemistry for NOVA2
Plan NOVA2 chromogenic IHC in paraffin sections around the nuclear staining observed in neuronal cells (HPA tissue IHC). This guide covers fixation consistency, antibody concentration, controls and interpretation of the differing cell-type annotations (datasheet A10622-2; UniProt; HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NOVA2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in neuronal cells (HPA tissue IHC) | |
| Staining pattern | Neuronal nuclei stain in brain tissue (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A10622-2) | |
| Positive control | Caudate+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Astrocyte annotation differs from neuronal IHC staining (UniProt tissue specificity; HPA tissue IHC) | |
| Regulation | Brain-enhanced RNA expression (HPA tissue RNA) | |
| Isoform / epitope | No isoforms or processing reported; one 1–492 chain (UniProt) |
Section 1
Recommended NOVA2 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet A10622-2) with three published NOVA2 paraffin-section IHC protocols (PMC12185593; PMC6157992; PMC6398979).
| Sample | Paraffin-embedded human appendicitis tissue; fixative not specified (datasheet A10622-2) |
| Fixation | Image fixative and duration unreported (datasheet A10622-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A10622-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A10622-2) |
| Primary antibody | Rabbit anti-NOVA2, 0.5-1μg/ml (datasheet A10622-2) |
| Primary incubation | Overnight at 4 °C (datasheet A10622-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A10622-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NOVA2-positive staining in neuronal cells of caudate (HPA tissue IHC: Medium). HPA tissue profile: Nuclear expression in neuronal cells. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 HIER for the catalog antibody (datasheet A10622-2). Citrate pH 6 was used with other antibodies (PMC12185593; PMC6157992).
Section 2
What Is the Expected NOVA2 Staining Pattern?
In paraffin-section IHC, expect predominantly nuclear NOVA2 staining in neuronal cells of the brain (HPA tissue IHC: nuclear neuronal profile; Enhanced reliability). HPA reports medium consistency between antibody staining and RNA expression (HPA tissue IHC: reliability description). UniProt places NOVA2 in the nucleus and reports no transmembrane segment (UniProt Q9UNW9: subcellular location and topology). UniProt also reports brain expression restricted to astrocytes, a cell-type assignment that differs from HPA's IHC profile (UniProt Q9UNW9: tissue specificity; HPA tissue IHC: profile).
| Distinct nuclear staining in neuronal cells of caudate, cerebral cortex, or hippocampus. | This matches the reported compartment and cell type; HPA records medium staining in neuronal cells at each of these sites (HPA tissue IHC: profile and positive tissues). Score the nuclei of identifiable cells rather than the overall darkness of the section, and compare them with the counterstain (standard IHC practice). |
| Prominent cytoplasmic or membranous staining in brain cells, with little nuclear signal. | That distribution conflicts with the nuclear tissue-IHC profile and UniProt location (HPA tissue IHC: profile; UniProt Q9UNW9: subcellular location). Treat it as a questionable IHC result and examine control sections and detection background before assigning it to NOVA2 (standard IHC practice). HPA's separate ICC-IF Golgi observation does not establish a cytoplasmic paraffin-IHC pattern (HPA subcellular ICC-IF: main location). |
| Strong staining in an unexpected cell population, such as adipocytes in adipose tissue. | HPA reports NOVA2 as undetected in adipocytes there (HPA tissue IHC: adipose tissue). Consider nonspecific antibody binding or endogenous detection activity, then check a section processed without primary antibody (standard IHC practice). Do not label every nonneuronal cell positive by default: HPA also reports medium staining in lung endothelial cells (HPA tissue IHC: lung). |
| Diffuse chromogen across tissue, including areas without clear cell boundaries or nuclear enrichment. | A widespread haze obscures the reported nuclear neuronal pattern (HPA tissue IHC: profile). Possible workflow causes include excess primary or detection reagent, inadequate washing, or endogenous detection activity (standard IHC practice). Judge cell-specific staining only after background is low enough to resolve nuclei and tissue structures (standard IHC practice). |
| No staining in neuronal cells of a caudate, cerebral-cortex, or hippocampal control section. | These are reported medium-positive populations, so an entirely blank run needs investigation (HPA tissue IHC: positive tissues). Check control-section integrity, reagent delivery, retrieval conditions, and detection performance using the validated IHC workflow (standard IHC practice). HPA's Enhanced rating supports the reported pattern but does not guarantee signal in every preparation (HPA tissue IHC: reliability). |
💡Expected NOVA2 appearanceCall an IHC result consistent with NOVA2 when identifiable neuronal nuclei show a clear, cell-resolved chromogenic signal against low background; HPA reports medium staining in the listed brain populations (HPA tissue IHC: profile and positive tissues). Predominantly membranous stain or uniform tissue-wide color is a questionable positive result (UniProt Q9UNW9: nuclear location and no transmembrane segment; standard IHC practice).
| Tissue and cell selection | Caudate, cerebral cortex, and hippocampus provide reported medium-positive neuronal populations; cerebellar molecular-layer cells are also medium positive (HPA tissue IHC: positive tissues). Adipose-tissue adipocytes and colon endothelial cells are reported undetected and can help assess cell-specific background (HPA tissue IHC: negative tissues). |
| Cell-type evidence | HPA describes nuclear expression in neuronal cells, while UniProt states brain expression is restricted to astrocytes (HPA tissue IHC: profile; UniProt Q9UNW9: tissue specificity). Record the morphology of stained cells and avoid resolving that disagreement from chromogen color alone (standard IHC practice). HPA rates tissue-IHC reliability Enhanced, with medium staining-to-RNA consistency (HPA tissue IHC: reliability). |
| Antibody evidence and target structure | HPA045607 has an Enhanced IHC validation status (HPA antibodies: HPA045607). NOVA2 is recorded as one chain, with no signal peptide, transmembrane segment, or listed isoforms (UniProt Q9UNW9: processing, topology, isoforms). These annotations support a nuclear interpretation but do not identify the antibody epitope or predict retrieval sensitivity (UniProt Q9UNW9: subcellular location; supplied record: no epitope or fixation-effect data). |
| IF/ICC Q&A: should fluorescence show only nuclei? | No single compartment can be carried over from paraffin IHC: HPA's ICC-IF summary places NOVA2 mainly at the Golgi apparatus, with additional nucleoplasm and nuclear-body signal, and rates HPA045607 ICC Approved (HPA subcellular ICC-IF; HPA antibodies: HPA045607). Interpret fluorescence on its own guide page while retaining the nuclear neuronal profile for tissue IHC (HPA tissue IHC: profile). |
| Situation | Likely cause | Next action |
|---|---|---|
| The expected brain control is blank. | The selected neuronal population is reported medium positive, so absent signal may reflect a failed IHC run or unsuitable section rather than a valid negative call (HPA tissue IHC: caudate, cerebral cortex, hippocampus; standard IHC practice). | Repeat with an intact reported-positive brain section; verify the IHC-validated antibody, retrieval, primary incubation, detection reagents, and counterstain against the validated workflow (HPA antibodies: HPA045607 IHC Enhanced; standard IHC practice). |
| Every compartment is brown, including reported-negative cells. | Broad staining can arise from nonspecific binding or endogenous detection activity (standard IHC practice). It is inconsistent with HPA's cell-resolved nuclear neuronal profile and undetected adipose adipocytes (HPA tissue IHC: profile; adipose tissue). | Run a no-primary section, inspect the detection system's endogenous-activity control, and optimize blocking, washing, and reagent concentration as appropriate for that system (standard IHC practice). |
| Nuclei appear weak against a strong counterstain. | The counterstain can reduce visual contrast, while the reported positive populations are only medium intensity (standard IHC practice; HPA tissue IHC: positive tissues). | Compare with the known-positive section in the same run and adjust counterstain strength and imaging exposure before changing the interpretation threshold (standard IHC practice; HPA tissue IHC: positive tissues). |
| Cytoplasm dominates the signal in brain tissue. | That pattern differs from HPA's nuclear tissue-IHC profile (HPA tissue IHC: profile). ICC-IF Golgi localization is a separate assay observation and cannot by itself validate this paraffin-IHC result (HPA subcellular ICC-IF: main location). | Inspect morphology and a no-primary control; compare nuclear and cytoplasmic signal in the same identifiable cells, then reassess antibody and detection conditions (standard IHC practice). |
| Staining appears in lung endothelial cells. | This is a reported medium IHC finding, even though HPA summarizes the overall profile as nuclear expression in neuronal cells (HPA tissue IHC: lung and profile). | Assess whether the signal is cell-resolved and nuclear, and compare it with the no-primary control; do not reject lung endothelial staining solely because the brain profile is neuronal (HPA tissue IHC: lung and profile; standard IHC practice). |
| A change in retrieval conditions changes staining intensity. | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. | Compare conditions on matched positive and negative control sections, keeping detection and scoring consistent; report the observed effect as an assay result without attributing it to a documented NOVA2 epitope mechanism (standard IHC practice). |
Experiment evidence
IHC & IF images showing NOVA2 staining
A10622-2 · IHCIHC analysis of NOVA2 using anti-NOVA2 antibody (A10622-2). NOVA2 was detected in paraffin-embedded section of human appendicitis tissue. He
A10622-2 · IHCIHC analysis of NOVA2 using anti-NOVA2 antibody (A10622-2). NOVA2 was detected in paraffin-embedded section of mouse brain tissue. Heat medi
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000104967-NOVA2/tissue/cerebral+cortex#imid_12141721
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000104967-NOVA2/tissue/colon#imid_12141639
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000104967-NOVA2/tissue/liver#imid_12141640
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000104967-NOVA2/tissue/kidney#imid_12141649
HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA045607; green = NOVA2, blue = nucleus, red = microtubules.
HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA045607; green = NOVA2, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NOVA2 IHC & IF
🧪Run caudate first and score neuronal cells for NOVA2 staining (HPA: Medium in caudate neuronal cells). Use adrenal gland glandular cells as the negative tissue (HPA: Not detected); on the caudate slide, adjacent cells without specific staining should show only background, assessed separately from the neuronal cells (HPA: Medium in neuronal cells).
Positive control tissue: Caudate (Neuronal cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NOVA2 in AF22, HUVEC/TERT2, U2OS, with annotated localisation: Golgi apparatus (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a rabbit immunoglobulin isotype control matched to the primary antibody’s clonality (caption: rabbit anti-NOVA2; standard IHC practice). Confirm specificity with NOVA2 knockout material or immunizing-peptide competition when the peptide is available (standard IHC practice). For caudate, quench endogenous peroxidase and assess endogenous biotin if using the caption’s biotin-based DAB detection (caption: biotinylated secondary, SABC and DAB; standard IHC practice).
⚠️Feasibility: No NOVA2-specific fixation window or fixation effect is reported, and the selected tissue-IHC caption does not state a fixative (caption: fixative unreported). Its paraffin-section result used heat retrieval in EDTA at pH 8.0, but it does not establish whether retrieval is required in caudate; the reported appendicitis staining also warrants checking against the HPA result for appendix glandular cells (caption: appendicitis staining and EDTA retrieval; HPA: Not detected in appendix glandular cells). The supplied evidence does not establish that frozen sections or IF are easier; brain autofluorescence should be assessed if caudate is examined by IF (HPA: Medium in caudate neuronal cells; standard IF practice).
HPA tissue IHC evidence for NOVA2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Caudate | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Cells in molecular layer | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Hippocampus | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Lung | Endothelial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NOVA2 IHC Tips
Troubleshoot NOVA2 staining in paraffin sections by checking retrieval, cell identity, subcellular pattern, and assay controls before assigning biological meaning.
What retrieval should I try first when NOVA2 staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet A10622-2). The selected paraffin-section image used this retrieval before incubation with 1 μg/ml antibody overnight at 4°C (datasheet A10622-2). If staining remains weak, vary heating time on matched sections while holding antibody concentration and detection conditions constant; excessive heating can damage morphology (standard IHC practice). Include a positive-control section in the same run and judge improvement by a clear cellular signal rather than overall DAB darkness (standard IHC practice). Record retrieval conditions for each slide so differences in nuclear staining can be traced to processing rather than assumed to reflect NOVA2 abundance.
Could fixation explain weak or uneven NOVA2 staining?
Target-specific sensitivity of NOVA2 staining to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state its fixative (datasheet A10622-2). Document the fixative and fixation duration for each specimen, then compare sections processed and retrieved together using EDTA at pH 8.0 (datasheet A10622-2; standard IHC practice). If staining differs, inspect tissue preservation, section thickness, retrieval consistency, and the positive control before attributing the difference to fixation (standard IHC practice). The caption reports an overnight incubation at 4°C, which offers a documented starting condition for comparison (datasheet A10622-2). Do not assign a NOVA2-specific fixation effect without a controlled comparison.
Should NOVA2 staining appear in nuclei, cytoplasm, or both?
For chromogenic tissue IHC, prioritize a distinct nuclear pattern in the expected cells: NOVA2 is annotated as nuclear, and tissue IHC reports nuclear expression in neuronal cells (UniProt Q9UNW9; HPA tissue IHC). Subcellular ICC/IF data also place NOVA2 mainly at the Golgi apparatus, with nucleoplasm and nuclear bodies as additional locations (HPA subcellular). These observations come from different assay contexts, so document nuclear and cytoplasmic staining separately rather than forcing one pattern onto every specimen. Compare each compartment with hematoxylin-defined nuclei and tissue morphology, and inspect the no-primary control for diffuse DAB deposition (standard IHC practice). Treat an isolated Golgi-like tissue pattern as requiring independent validation.
How should I troubleshoot an apparent NOVA2 epitope or isoform discrepancy?
The supplied record lists a single 492-amino-acid chain, no annotated isoforms, and three KH domains at residues 32–99, 130–196, and 406–473 (UniProt Q9UNW9). It also lists no signal peptide, transmembrane segment, glycosylation sites, or modified residues (UniProt Q9UNW9). Those annotations do not identify the catalog antibody's epitope or establish whether retrieval exposes it (UniProt Q9UNW9; datasheet A10622-2). If a suspected epitope issue arises, request the antibody's immunogen information and compare retrieval conditions on matched sections while keeping detection fixed (standard IHC practice). Avoid explaining discrepant staining by an unlisted isoform or post-translational modification.
How can I assess NOVA2 by IF alongside a cell identity marker?
For a separate IF/ICC experiment, pair NOVA2 with a validated neuronal marker when examining the neuronal tissue-IHC pattern; tissue IHC describes nuclear signal in neuronal cells (HPA tissue IHC). Choose spectrally separated fluorophores and place the weaker signal in a channel with low tissue autofluorescence, checking single-stain and unstained controls (standard IF practice). Because the reported nuclear, nucleoplasmic, nuclear-body, and Golgi locations are intracellular, use fixation-compatible permeabilisation and assess its effect on both markers (UniProt Q9UNW9; HPA subcellular; standard IF practice). Score nuclear and Golgi-like signal separately and verify cell identity with the marker. The paraffin-section retrieval and 1 μg/ml incubation describe IHC evidence, not an established IF condition (datasheet A10622-2).
What should I check when DAB obscures discrete NOVA2 staining?
The selected paraffin-section example used 10% goat serum, a biotinylated secondary, a streptavidin-biotin complex, and DAB (datasheet A10622-2). For that detection scheme, inspect no-primary and secondary-only controls, block endogenous peroxidase, and check for endogenous biotin signal where relevant (standard chromogenic IHC practice). Shorten DAB development or titrate the primary below the documented 1 μg/ml condition if diffuse staining persists, comparing matched sections in the same run (datasheet A10622-2; standard IHC practice). Edges, folds, damaged areas, and poorly preserved tissue can accumulate misleading chromogen (standard IHC practice). Evaluate whether any remaining signal resolves into reproducible cellular compartments before calling it NOVA2.
How should I quantify NOVA2 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and cell class before scoring: HPA tissue IHC reports neuronal nuclear expression in several brain regions and endothelial staining in lung (HPA tissue IHC). Within each prespecified class, report the percentage of positive nuclei and an intensity-based H-score from 0–300, or positive-cell density per mm² when cell counts are the endpoint (standard IHC practice). Normalize positive counts to the number of evaluable cells in that class, or density to analyzed tissue area, using the same threshold across matched slides. Exclude folds, necrosis, and section edges by a recorded rule (standard IHC practice). Report cytoplasmic signal separately because it should not inflate a nuclear score.
When is a NOVA2-positive IHC result convincing?
A convincing result shows reproducible cellular staining in an appropriate compartment and cell population: tissue IHC reports nuclear signal in neuronal cells, while UniProt annotates NOVA2 as nuclear (HPA tissue IHC; UniProt Q9UNW9). HPA also reports lung endothelial staining, whereas appendix glandular cells were not detected; the selected appendicitis paraffin image alone does not identify its stained cell class (HPA tissue IHC; datasheet A10622-2). Compare morphology and controls before interpreting staining outside those contexts. Reject edge accentuation, necrotic deposits, or signal reproduced by a no-primary control as evidence of target expression (standard IHC practice). Investigate a purely cytoplasmic or unexpected-cell pattern with an independent antibody or assay before assigning NOVA2 identity.
Boster reagents
Best NOVA2 / RNA-binding protein Nova-2 IHC Antibodies
The IHC-validated anti-NOVA2 antibody has paraffin-section images from human appendicitis tissue and mouse and rat brain (catalog IHC captions). No IF/ICC data are supplied (catalog applications and images).
Real IHC data
Anti-NOVA2 Antibody ®
Cat # A10622-2
A10622-2 has IHC images from human appendicitis tissue and mouse and rat brain paraffin sections (A10622-2 IHC captions). Its listed applications include IHC, and its stated reactivity covers human, mouse and rat (catalog applications and reactivity).
Which to pick: For tissue IHC, choose A10622-2: its captions document paraffin sections, EDTA retrieval at pH 8.0 and DAB detection; the fixative is unreported (A10622-2 IHC captions). No IF/ICC-validated option is listed, and A10622-2 has no IF/ICC figure; its clonality is unreported (catalog applications, IF images and clone field). For cross-species IHC, A10622-2 has human, mouse and rat reactivity and a paraffin-section caption for each species (catalog reactivity; A10622-2 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UNW9 (NOVA2_HUMAN, RNA-binding protein Nova-2).
- Human Protein Atlas. NOVA2 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. NOVA2 subcellular location (ICC-IF): Mainly localized to the Golgi apparatus. In addition localized to the nucleoplasm and nuclear bodies..
- Human Protein Atlas. NOVA2 antibody validation summary (1 antibodies).
- NOVA2 expression in pituitary gland and in functioning and non-functioning pituitary adenomas: a preliminary study. Acta neurochirurgica 2025 — PMC12185593.
- Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature. OncoTargets and therapy 2018 — PMC6157992.
- A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. eLife 2019 — PMC6398979.
- NOVA2-mediated RNA regulation is required for axonal pathfinding during development. eLife 2016 — PMC4930328.
- PubMed PMID:10735272 — UniProt-cited evidence.
- PubMed PMID:9789075 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NOVA2 (RNA-binding protein Nova-2). Expected localisation Nuclear staining in neuronal cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A10622-2). Validated IHC antibody: A10622-2 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Caudate (Neuronal cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human appendicitis tissue; fixative not specified (datasheet A10622-2); 2. Fixation: Image fixative and duration unreported (datasheet A10622-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A10622-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A10622-2); 8. Primary antibody: Rabbit anti-NOVA2, 0.5-1μg/ml (datasheet A10622-2); 9. Primary incubation: Overnight at 4 °C (datasheet A10622-2). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Astrocyte annotation differs from neuronal IHC staining (UniProt tissue specificity; HPA tissue IHC); Isoform / epitope: No isoforms or processing reported; one 1–492 chain (UniProt); Regulation: Brain-enhanced RNA expression (HPA tissue RNA). Evidence: UniProt Q9UNW9, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the Golgi apparatus. In addition localized to…, Datasheet A10622-2, PMC12185593, PMC6157992. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NOVA2/immunohistochemistry-ihc-guide.